UNSPSC 51321702: Eicosapentaenoic acid

This classification denotes an eicosapentaenoic acid with the molecular formula C20H30O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AAN7QOV9EA, chemically known as icosa-5,8,11,14,17-pentaenoic acid but generally known as eicosapentaenoic acid, which bears US NIH Compound Identifier 3209. European Medicines Agency schedules Eicosapentaenoic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13664MIG.

The term ICOSAPENT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). Eicosapentaenoic acid bears US NLM identifiers UMLS ID C0000545 and NCI Concept Code C67080. SMILES: OC(=O)CCC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CC.

UNSPSC 51321702 Eicosapentaenoic acid is a Commodity code that covers pharmaceutical active pharmaceutical ingredients and finished medications, though the recent state and local opportunities tagged under it show wider pharmaceutical procurement activity than the code's specific name suggests. State and local governments soliciting under this code are acquiring emergency medical supplies, generic pharmaceuticals for multi-state cooperative purchasing programs, and exploring direct-to-manufacturer pharmacy benefit arrangements. The issuing bodies span municipal fire departments, state health and human services commissions, and multi-state cooperative purchasing alliances, with activity driven by both routine supply replenishment and strategic pharmacy program redesign.

Recent opportunities include the City of Tampa's Purchasing Department bid (26P00188) for Advanced Life Support Medications needed by Tampa Fire Rescue—a sealed-bid IFB for four specific ALS medication line items with an estimated contract value of $40,000 and a response deadline of April 8, 2026; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with responses due March 26, 2026; and the Texas Health and Human Services Commission's RFI (HHS0017013) exploring vendor capabilities for direct-to-manufacturer pharmacy programs, posted April 3, 2026. Activity concentrates in Florida, Minnesota, Oregon, and Texas, with the MMCAP cooperative covering multi-state distribution and the Texas HHS effort signaling state-level interest in alternative pharmacy benefit models. The code shows activity across municipal procurement, state agency programs, and cooperative purchasing vehicles, with contract terms typically one to two years and optional renewals or extensions.